Senzime AB (publ) (STO: SEZI)

Market Cap	781.60M
Revenue (ttm)	55.29M
Net Income (ttm)	-131.46M
Shares Out	132.47M
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,209
Average Volume	112,369
Open	5.96
Previous Close	6.00
Day's Range	5.89 - 6.04
52-Week Range	5.40 - 9.60
Beta	0.59
RSI	50.78
Earnings Date	Feb 17, 2025

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 52
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SEZI

Financial Performance

In 2023, Senzime AB's revenue was 35.75 million, an increase of 154.77% compared to the previous year's 14.03 million. Losses were -134.15 million, 1.09% more than in 2022.